Previous research has shown that frontline treatment with pembrolizumab + platinum-based chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC; squamous or non-squamous without epidermal growth factor receptor [EGFR]/anaplastic lymphoma kinase [ALK] mutation) irrespective of PD-L1 expression improves clinical outcomes when compared to standard chemotherapy alone[1-3]. However, more knowledge and insights are required with regard to outcomes for pembrolizumab + chemotherapy in patients without PD-L1 expression as these patients are not eligible for treatment with pembrolizumab monotherapy.
Borghaei et al. aimed to put together a pooled analysis of pembrolizumab + chemotherapy in patients with advanced/metastasised NSCLC without PD-L1 expression (tumour proportion score [TPS] <1%) which was based on 3 randomised trials: KEYNOTE-021, KEYNOTE-189, and KEYNOTE 407 [4-6]. These 3 studies held a total of 1,298 patients. Of those, 33.0% had a...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« New Technologies in Lung Cancer Detection Next Article
Durvalumab Added to Etoposide Improves Outcomes in ES-SCLC »
Table of Contents: WCLC 2019
Screening, Detection, and Diagnosis
Non-Small-Cell Lung Cancer
Other Thoracic Malignancies
Phase 3 Trial Updates
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.